It’s Still Too Early to Buy CVS
CVS (CVS) was a great stock for three-and-a-half decades, then slower sales and profits brought the stock down. I feel CVS will make a comeback, but not just yet.
CVS (CVS) was a great stock for three-and-a-half decades, then slower sales and profits brought the stock down. I feel CVS will make a comeback, but not just yet.
CVS (CVS) is dead money for now as profit growth looks to be flat this year. But profits could grow 10% in 2018, and that could bring life into the stock.
CVS Caremark (CVS) is dealing with some issues that will likely keep it around here for a while. But CVS is still a high quality stock — and it’s cheap.
In a stunning turn of events for one of the steadiest companies the past decade, CVS (CVS) said it’s losing 40 million scripts and slashed guidance.
CVS (CVS) has been a weak performer this year, and that has made the stock a good value. CVS could be set to rally as profit growth is expected to accelerate.
CVS Caremark (CVS) has been underperforming lately as the pharmacy benefit management business has serious competition from OptumRx.
CVS (CVS) has qualities many investors will love, such as a streak of growing profits since 2002, solid safety rating, and a decent dividend.
In a turbulent stock market such as this, CVS (CVS) can give investors safety in addition to growth, and a dividend as well.
Today I will use the market weakness to pick up three core holdings at a discounted price.
CVS (CVS) is promoting a healthy lifestyle, while expanding its drug distribution business through acquisitions, and the stock is a good selection for conservative investors.
Today CVS Caremark (CVS) changed its name to CVS Health. So let’s look at the stock…
Looking for a stock that can compound at 15% a year? CVS Caremark (CVS) has done that. But don’t buy high. Bide your time.